Who Should Take Hormone Replacement Therapy? The Short Answer
Menopause hormone therapy may be an appropriate option for healthy women experiencing bothersome hot flashes, night sweats or other menopause-related symptoms—particularly when treatment begins before age 60 or within 10 years of menopause. The decision depends on symptoms, medical history, cardiovascular and breast cancer risk, uterine status and personal preferences. At Azani Medical Spa in Bethlehem, PA, an individualized medical evaluation can help women understand potential benefits, risks and alternatives.
At a Glance: Who May Be a Candidate for Menopause HRT?
| Consideration | What It Means |
|---|---|
| Menopause symptoms | Moderate to severe hot flashes, night sweats or other bothersome symptoms may support treatment |
| Age and timing | Benefit-risk balance is generally most favorable for appropriate women younger than 60 or within 10 years of menopause |
| Medical history | Breast cancer, blood clots, stroke, cardiovascular disease, liver disease and unexplained bleeding require careful assessment and may contraindicate systemic therapy |
| Uterus | Women with an intact uterus generally need adequate progestogen with systemic estrogen |
| Treatment goals | Symptom relief and selected bone-protection goals—not guaranteed longevity, dementia prevention or heart disease prevention |
| Personalization | Hormone type, route, dose and regimen should reflect individual risk and preferences |
| Follow-up | Periodic reassessment is important to evaluate ongoing benefits, risks and treatment goals |
These principles are consistent with The Menopause Society’s hormone therapy position statement and the 2025 European Society of Endocrinology menopause guideline.
1. Age and Timing: Why They Matter
One of the most important considerations when evaluating menopause hormone therapy is when treatment begins relative to menopause.
For most healthy women without contraindications, the benefit-risk ratio is generally favorable when systemic hormone therapy is initiated:
- Before age 60, or
- Within 10 years of menopause onset,
particularly when treating bothersome vasomotor symptoms such as hot flashes and night sweats.
This is often described as the timing hypothesis or the menopause hormone therapy window.
Why the early menopause window matters
As women age and move farther from menopause, their underlying absolute risks of cardiovascular disease, stroke, venous thromboembolism and other conditions increase. Initiating systemic hormone therapy later may therefore produce a less favorable balance of benefits and risks.
This does not mean hormone therapy automatically becomes inappropriate at age 60 or after 10 years of menopause. It means that starting treatment later requires more careful consideration of the individual’s medical history, symptoms, risk profile and treatment alternatives.
The decision to continue established therapy is also different from the decision to initiate it for the first time.
Evidence note: The Menopause Society’s 2022 position statement and the European Society of Endocrinology’s 2025 guideline support considering age, time since menopause and individual health characteristics when evaluating treatment.
2. Symptoms That May Support Hormone Therapy
Systemic menopause hormone therapy is most established for treating bothersome vasomotor symptoms.
Hot flashes and night sweats
Hot flashes and night sweats can interfere with sleep, work, relationships and overall quality of life. Systemic estrogen is the most effective treatment for these symptoms in appropriate candidates.
Women who experience frequent or disruptive symptoms may benefit from discussing hormone therapy with a qualified healthcare professional.
Sleep disruption and menopause-related symptoms
Some women experience poor sleep, fatigue, irritability or difficulty concentrating during menopause.
These symptoms may be associated with hot flashes, night sweats, mood changes or other conditions. Hormone therapy may improve some symptoms indirectly when it successfully reduces vasomotor symptoms, but it is not a universal treatment for insomnia, depression or cognitive complaints.
Vaginal dryness, painful intercourse and urinary symptoms
Genitourinary syndrome of menopause (GSM) includes symptoms such as:
- Vaginal dryness or irritation
- Pain during sexual activity
- Burning or discomfort
- Certain urinary symptoms
Women whose symptoms are primarily genitourinary may not need systemic hormone therapy.
Low-dose vaginal estrogen and other local or non-estrogen treatments may be appropriate options depending on symptoms, medical history and patient preference. Low-dose vaginal estrogen is distinct from systemic hormone therapy and is generally used to treat local symptoms rather than hot flashes.
3. Medical History: When Hormone Therapy May Not Be Appropriate
A careful medical history is essential before prescribing systemic menopause hormone therapy.
Certain conditions can substantially change the safety assessment and may contraindicate systemic estrogen.
Important conditions requiring assessment
| Medical History | Why It Matters |
|---|---|
| Breast cancer or other estrogen-dependent cancer | Systemic estrogen may be inappropriate; specialized oncology and menopause consultation may be necessary |
| Previous stroke or myocardial infarction | Vascular risk may make systemic therapy unsuitable |
| Venous thromboembolism (DVT or pulmonary embolism) | Estrogen can affect clotting risk; history requires careful evaluation |
| Known thrombophilia | May substantially increase thromboembolic risk |
| Active or significant liver disease | Can affect hormone metabolism and treatment suitability |
| Unexplained vaginal bleeding | Requires evaluation before hormone therapy |
| Cardiovascular disease or substantial cardiovascular risk | Requires individualized risk assessment and may preclude systemic treatment |
These are not simply boxes to check. The severity, timing and nature of a condition matter, and selected situations may require specialist input.
Important: A transdermal estrogen route may have a different risk profile than oral estrogen for some outcomes, but it does not automatically eliminate contraindications or make systemic therapy safe for every patient.
For additional patient guidance, see ACOG’s Hormone Therapy for Menopause FAQ.
4. Does Having a Uterus Change Which Hormones You Need?
Yes. Uterine status is a central consideration in choosing a hormone regimen.
Women who have an intact uterus
Systemic estrogen stimulates the endometrium. In women with an intact uterus, adequate progestogen is generally required to protect against estrogen-induced endometrial hyperplasia and endometrial cancer.
The regimen, dose and duration of progestogen must be appropriate for the estrogen being used.
Women who have had a hysterectomy
Women without a uterus may often use estrogen alone, depending on their medical history and the type of hysterectomy performed.
Exceptions and special circumstances exist, so prior surgery and relevant gynecologic history should be reviewed rather than assuming that every hysterectomy automatically means estrogen-only treatment.
Why this matters in BHRT discussions
The term bioidentical describes a hormone’s molecular structure. It does not determine whether a woman needs estrogen alone or estrogen plus progesterone.
FDA-approved estradiol and micronized progesterone are examples of bioidentical hormones. The appropriate combination depends on the patient’s anatomy, symptoms, risks and clinical goals.
For a deeper comparison, read FDA-Approved Bioidentical Hormones vs. Compounded Bioidentical HRT: What’s the Difference?.
5. What About Women With Early Menopause or Primary Ovarian Insufficiency?
Women who experience menopause substantially earlier than the average age—including women with primary ovarian insufficiency (POI)—represent a different clinical situation.
When ovarian estrogen production ends prematurely, hormone therapy may be recommended until approximately the average age of natural menopause, unless contraindications exist.
The rationale includes supporting bone health and addressing consequences of premature estrogen deficiency, even when classic hot flashes are not the primary complaint.
This is not identical to initiating hormone therapy for the first time in an otherwise typical postmenopausal woman in her 60s or 70s.
Early menopause and POI therefore deserve individualized assessment rather than applying the usual age-and-timing framework without modification.
6. Is Hormone Therapy Appropriate for Heart Health, Brain Health or Longevity?
Hormone therapy should not be prescribed solely to prevent cardiovascular disease, dementia or aging.
Although estrogen has important biological effects on vascular, skeletal and neurologic systems, these mechanisms do not establish that systemic menopause hormone therapy prevents heart attacks, Alzheimer’s disease or extends lifespan.
For appropriate symptomatic women, hormone therapy may have additional benefits, including preventing bone loss and reducing fracture risk. These benefits must still be balanced against individual risks.
Explore the evidence in our related articles:
- Does Menopause Hormone Therapy Protect Your Heart?
- Does Estrogen Help Brain Health, Memory or Prevent Dementia After Menopause?
- Bioidentical Hormones and Longevity: Can HRT Help You Live Longer?
- Can Bioidentical Hormones Protect Your Bones?
7. What Should a Personalized BHRT Evaluation Include?
A thoughtful menopause hormone therapy consultation should begin with the patient’s symptoms, health history and treatment goals—not with a predetermined hormone prescription.
A comprehensive evaluation may consider:
- Menopause history: Age, menstrual history, timing of menopause and prior hormone use.
- Symptoms: Hot flashes, night sweats, sleep disruption, vaginal or urinary symptoms, mood concerns and quality-of-life effects.
- Medical history: Cardiovascular disease, blood clots, cancer history, liver disease, migraines, metabolic conditions and other relevant diagnoses.
- Family history: Particularly breast cancer, cardiovascular disease and relevant hereditary conditions.
- Uterine status: Whether the uterus is intact, prior gynecologic procedures and any abnormal bleeding.
- Medications and supplements: Potential interactions and relevant prior treatment responses.
- Risk assessment: Cardiovascular, thromboembolic, breast cancer and bone-health considerations when clinically indicated.
- Treatment preferences: Oral versus transdermal options, symptom priorities, tolerance, convenience and affordability.
- Alternatives: Nonhormonal treatments and local therapies when systemic hormones are not appropriate or preferred.
Testing should be selected according to clinical indications. No single laboratory panel can determine whether every woman should receive BHRT, and hormone testing alone cannot replace a medical history and risk assessment.
8. How Dr. Monica Gavin and Azani Medical Spa Approach the Next Step
For women considering menopause hormone therapy, the most useful next step is an informed discussion of symptoms, goals, health history and available treatment options.
At Azani Medical Spa in Bethlehem, Pennsylvania, Dr. Monica Gavin can help women explore whether hormone therapy may be appropriate and understand the considerations involved in individualized care.
A consultation is an opportunity to discuss:
- Which menopause symptoms are most important to address
- Whether systemic or local therapy may be appropriate
- Potential benefits, limitations and risks
- Whether additional evaluation or coordination with another healthcare professional is needed
- FDA-approved hormone options and alternatives
- How treatment decisions can be reassessed over time
The goal is not to prescribe hormones to every woman experiencing menopause. It is to help each woman make an informed decision based on her medical circumstances and preferences.
Interested in discussing menopause hormone therapy?
Learn more about Women’s Hormone Replacement Therapy at Azani Medical Spa or request a consultation.
Call 610-625-3000 or text 610-625-3002 to contact Azani Medical Spa.
Who should take hormone replacement therapy?
Women with bothersome menopause symptoms, particularly healthy women younger than 60 or within 10 years of menopause, may be appropriate candidates if they have no contraindications. Treatment should be individualized following medical evaluation.
Is HRT safe for women over 60?
It may be appropriate for selected women, but starting systemic hormone therapy after age 60 or more than 10 years after menopause generally requires more careful assessment because the benefit-risk balance may be less favorable. Age alone does not automatically require discontinuation of established therapy.
Can women with a history of breast cancer take BHRT?
Systemic hormone therapy is generally not recommended for women with a personal history of breast cancer. Some women with genitourinary symptoms may have options such as low-dose vaginal estrogen after individualized discussion with their oncology and menopause care teams.
Do women need progesterone if they take estrogen?
Women with an intact uterus generally need adequate progestogen alongside systemic estrogen to protect the endometrium. Women who have had a hysterectomy may often use estrogen alone, depending on their clinical history.
Can hormone therapy prevent Alzheimer’s disease or heart disease?
Hormone therapy is not recommended solely to prevent dementia or cardiovascular disease. It is primarily used to treat bothersome menopause symptoms in appropriate candidates and may provide bone-protection benefits.
Does every woman need hormone testing before BHRT?
No. Hormone testing is not universally required to determine whether menopause hormone therapy is appropriate. Testing should be guided by symptoms, clinical history and specific medical questions.
What is the difference between FDA-approved BHRT and compounded BHRT?
FDA-approved bioidentical hormones have undergone FDA review for their specific indications, quality, safety and efficacy. Compounded hormone preparations are not FDA-approved and do not have the same premarket review. Compounded products may be appropriate for specific medical needs when approved options cannot meet them, but they are not automatically safer or more effective.
Read FDA-Approved Bioidentical Hormones vs. Compounded Bioidentical HRT.
Where can I discuss menopause hormone therapy in Bethlehem, PA?
Azani Medical Spa offers information and consultation opportunities for women considering hormone therapy. Visit the Women’s Hormone Replacement Therapy page or contact the practice to discuss next steps.
Medical Disclaimer
This article is for educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. Menopause hormone therapy has potential benefits and risks that vary by patient, formulation, dose, route, timing and medical history. Decisions about starting, changing or discontinuing hormone therapy should be made with a qualified healthcare professional.
Last reviewed: November 13, 2026